Bazlitoran is under investigation in clinical trial NCT02092909 (Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).
Bazlitoran is under investigation in clinical trial NCT02092909 (Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.